Valuation: EyePoint, Inc.

Market Cap 1.08B 937M 872M 801M 1.51B 103B 1.54B 10.28B 4.04B 51.24B 4.05B 3.96B 172B P/E 2026 *
-3.61x
P/E 2027 * -4.33x
Enterprise Value 784M 681M 634M 582M 1.1B 74.83B 1.12B 7.48B 2.93B 37.25B 2.94B 2.88B 125B EV / Sales 2026 *
448x
EV / Sales 2027 * 27.9x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day-5.05%
1 week-0.53%
Current month-15.21%
1 month-8.11%
3 months-9.11%
6 months-8.77%
Current year-33.63%
1 week 11.56
Extreme 11.555
13.02
1 month 11.56
Extreme 11.555
14.99
Current year 11.3
Extreme 11.295
18.87
1 year 9.4
Extreme 9.4
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
42.5
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap.
10/7/26 Fiscal year

Chief Executive Officer

41,393 0.0494%
30/6/26 Fiscal year

Chief Technology Officer

14,625 0.0174%
23/3/26 Others

Chief Executive Officer

453,532 0.5478%
Change 5-day change 1-year change 3-year change Capi.($)
-5.09%-0.53%+23.47%-3.00% 1.08B
-0.62%-3.99%+55.17%+152.63% 1,030B
+0.66%-2.21%+56.36%+53.75% 617B
-1.85%-2.59%+33.66%+68.90% 455B
+0.06%-0.42%+37.53%+30.67% 350B
-0.14%-0.24%+34.41%+39.01% 299B
-0.69%-0.30%+11.55%+12.93% 265B
-7.37%-4.40%-2.54%-43.87% 225B
-0.40%+2.72%+30.89%+64.96% 209B
-0.37%+1.04%+16.36%+71.60% 163B
Average -1.54%+3.76%+29.69%+44.76% 361.37B
Weighted average by Cap. -0.81%+4.87%+39.27%+72.74%

Financials

2026 *2027 *
Net sales 1.75M 1.52M 1.42M 1.3M 2.46M 167M 2.5M 16.71M 6.56M 83.25M 6.58M 6.43M 279M 32.76M 28.48M 26.5M 24.33M 45.95M 3.13B 46.67M 312M 123M 1.56B 123M 120M 5.22B
Net income -316M -275M -256M -235M -444M -30.18B -450M -3.02B -1.18B -15.03B -1.19B -1.16B -50.38B -289M -251M -234M -215M -406M -27.6B -412M -2.76B -1.08B -13.74B -1.09B -1.06B -46.08B
Net Debt -294M -256M -238M -219M -413M -28.1B -419M -2.81B -1.1B -13.99B -1.11B -1.08B -46.9B -164M -142M -132M -122M -230M -15.62B -233M -1.56B -612M -7.78B -614M -601M -26.07B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
214
Date Price Change Volume
01/08/26 USD 12.13 -5.68% 986,937
30/07/26 USD 12.86 +7.89% 1,561,104
29/07/26 USD 11.92 -0.33% 2,054,155
28/07/26 USD 11.96 -3.63% 1,698,346
27/07/26 USD 12.41 +1.80% 1,390,307
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
12.86USD
Average target price
40.50USD
Spread / Average Target
+214.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock